We focus on biomarker-driven research to deliver personalized treatments and a transformative, risk-balanced pipeline.
Translational research is embedded in the entire R&D process. With our innovative approach to treatment and novel combinations we address unmet needs in hard-to-treat cancers.
Our pipeline comprises high-quality, selective small molecules, antibodies and antibody-drug conjugates (ADCs). Strong translational research data supports each drug’s clinical development, with the goal of clear differentiation and the potential to become first and/or best-in-class therapeutics.
We focus on five innovation clusters: Oncogenic Signaling, ADC, DNA Repair, Tumor Metabolism and Tumor Cell Plasticity. In Oncogenic Signaling, we have the resources to develop highly selective drugs against key enzymes. In other areas, partnerships are key to enhancing our capabilities. By collaborating with Mersana and Sutro, we gained access to technology platforms for developing next-generation ADCs. In DNA repair, we combined our pipeline with assets licensed from Vertex in 2017 and invested in both new target identification and translational research. As a result, we are positioned to assume leadership of the field. Further co-discovery partnerships maximize our leadership potential in Tumor Metabolism and Tumor Cell Plasticity.
Dedicated to delivering personalized medicine, we are aiming to identify patient populations likely to respond to treatment, to guide optimal dosing and to increase the probability of success in clinical development.
We believe that rational combination is key to developing new and more effective treatment options. For instance, with chemo/radiotherapy, other targeted therapies and/or immunotherapies.
We recognize that no single organization can achieve these goals alone. We partner with leading academic institutions and innovative biotech innovators to complement our pipeline, strengthen our technology base and enhance our scientific capabilities.
Browse the programs in our pipeline to see what we’re currently working on by phase, therapeutic area, and compound type. You can also see what we’ve discovered in-house versus those assets we’re partnering on with other giants in our industry. Learn more